The Middle East and Africa parenteral nutrition market size was valued at USD 203.6 million in 2016 and is expected to grow at a CAGR of 7.1% over the forecast period. Increasing natality rate, rising number of premature births, risk of malnutrition, and increasing prevalence of chronic disorders such as cancer are the key growth rendering drivers responsible for the lucrative growth of the market.
Saudi Arabia parenteral nutrition market, by type of nutrition, 2014 - 2025 (USD Million)
The natality rate indicates the total number of births per 1,000 people and is useful to understand the rise in the population of a region. Growth in population increases the burden of healthcare costs and food expenditure for a household as well as the nation. Thus, a higher birth rate is expected to impact the nutrition level, thereby acting as a driver for the market.
Most of the premature babies suffer from low weight and undeveloped immunity, which puts them at risk. These formulations diminish the risk of infection and underdevelopment, thus promoting its application. The demand for parenteral nutrition is higher in very low birth weight (VLBW) newborns due to the low prospect of enteral nutrition. Use of these formulations in premature infants leads to faster neurological development, improved intrauterine nutrient deposition, and minimized risk of complications, thereby improving their chances for survival.
Malnutrition is one of the major drivers of the market. According to the UNICEF, malnourishment in the first 1,000 days of an infant’s life may lead to impaired cognitive ability and stunted growth. An infant’s diet must contain a proper balance of starch, minerals, vitamins, amino acids, and lipids. These essential nutrients can be administered through parenteral nutrition, which is expected to boost market growth.
Increasing prevalence of chronic conditions such as cancer unswervingly impacts the use of parenteral nutrition across the country. Parenteral nutrition helps in the administration of vital nutrients that are useful in maintaining strength, energy, and hydration level amongst patients throughout the treatment regime.
Single-dose amino acid solutions held a substantial share in 2016. The increased usage of amino acid solutions can be attributed to an increase in the influx of regulatory approved solutions. Moreover, newly available amino acid solutions result in lesser adverse effects, thus enhancing care delivery.
Carbohydrates followed the single-dose amino acids segment in terms of market share in 2016. Also, intravenous lipid emulsions are projected to witness lucrative growth over the forecast period. Lipid emulsion parenteral formulation showcase promising results, reducing complications such as skin irritation, thrombophlebitis, and pain.
Parenteral nutrition can be supplied in various dosage forms, such as vials, ampoules, glass bottles, and bags. Bags are further sub-segmented into multi-chambered bags and others. Bags dominated the Middle East parenteral nutrition market with more than a 67.0% share in 2016. Bags are easy to handle, lightweight, and cost-efficient. Moreover, bags are also easy to dispose of after the administration of nutrient to the patient.
These bags can be single, dual, or triple-chambered. Although single-chambered bags are abundant in the market, vials are anticipated to gain substantial share over the forecast period. Vials are often used for smaller concentration doses and they are used in hospital compounding. Increasing focus on customized treatment is likely to boost the usage of vials.
MEA parenteral nutrition market, by dosage form, 2016 (%)
Saudi Arabia held a significant share of around 13.4% in 2016 due to the presence of the largest health care network and hospitals. Countries such as Kuwait, Oman, Lebanon, and Jordan are anticipated to gain remunerative share over the forecast period. Supportive government initiatives, an increasing number of healthcare settings, raising awareness, and increasing healthcare expenditure are likely to support their growth in the coming eight to nine years. The Health system in Qatar has improved in the past decade as a result of significant supportive investments by the government. The rate of child mortality has declined over the past couple of decades.
Qatar spent USD 4.7 billion on healthcare in 2014, which was the highest in the Middle East. Kuwait is anticipated to witness lucrative growth over the forecast period owing to supportive government initiatives for the expansion of health resources. Approximately 80% of the investment in the healthcare sector of Kuwait is made by the government. Kuwait has one of the most modern healthcare infrastructures in the region with adequate clinics, health centers, & hospitals backed by skilled healthcare staff equipped to provide safe & effective healthcare.
Key players of this market are B. Braun Melsungen AG; Baxter; Fresenius Kabi AG; Hospira Inc.; Qatar Pharma Factory; Pharmaceutical Solutions Industry; Kuwait Saudi Pharmaceutical Industries Co.; Alfa Laboratories; and Well Pharma. These companies are actively involved in improving their current product portfolio of parenteral nutrition to sustain their position in the market. Also, new drug development and their entry into untapped territories are expected to boost growth.
For instance, in 2015, B. Braun Melsungen AG invested around USD 1.1 Billion in R&D of new products and expansion of production capacities. For instance, it is constructing a new manufacturing unit in Melsungen for the production of individual nutritional solutions. This investment is expected to help the company increase its goodwill.
Report Attribute |
Details |
The market size value in 2020 |
USD 267.1 million |
The revenue forecast in 2025 |
USD 377.2 million |
Growth Rate |
CAGR of 7.1% from 2017 to 2025 |
The base year for estimation |
2016 |
Historical data |
2014 – 2016 |
Forecast period |
2017 – 2025 |
Quantitative units |
Revenue in USD million and CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Application, deployment, component, end-use, region |
Regional scope |
Middle East & Africa |
Country scope |
Saudi Arabia; Qatar; Kuwait; UAE; Oman; Egypt; Lebanon; Jordan |
Key companies profiled |
B. Braun Melsungen AG; Baxter; Fresenius Kabi AG; Hospira Inc.; Qatar Pharma Factory; Pharmaceutical Solutions Industry; Kuwait Saudi Pharmaceutical Industries Co.; Alfa Laboratories; Well Pharma |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at regional & country levels and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For this study, Grand View Research has segmented the MEA parenteral nutrition market based on the type of nutrients, dosage form, and region:
Nutrient Type Outlook (Revenue, USD Million; 2014 - 2025)
Carbohydrate
Parenteral Lipid Emulsions
Single Dose Amino Acid Solutions
Trace Elements
Vitamins and Minerals
Dosage Form Outlook (Revenue, USD Million; 2014 - 2025)
Vials
Ampoules
Bottles
Bags
Multi-chambered bags
Other bags
Regional Outlook (Revenue, USD Million; 2014 - 2025)
The Middle East and Africa
Saudi Arabia
Qatar
Kuwait
UAE
Oman
Egypt
Lebanon
Jordan
b. The global MEA parenteral nutrition market size was estimated at USD 249.5 million in 2019 and is expected to reach USD 267.1 million in 2020.
b. The global MEA parenteral nutrition market is expected to grow at a compound annual growth rate of 7.1% from 2017 to 2025 to reach USD 377.2 million by 2025.
b. Single dose amino acid solutions dominated the MEA parenteral nutrition market with a share of 32% in 2019. This is attributable to increase in influx of regulatory approved solutions.
b. Some key players operating in the MEA parenteral nutrition market include B. Braun Melsungen AG; Baxter; Fresenius Kabi AG; Hospira Inc.; Qatar Pharma Factory; Pharmaceutical Solutions Industry; Kuwait Saudi Pharmaceutical Industries Co.; Alfa Laboratories; and Well Pharma.
b. Key factors that are driving the market growth include increasing natality rate, rising number of premature births, risk of malnutrition, and increasing prevalence of chronic disorders such as cancer.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.